Cyclerion Therapeutics, Inc.
CYCN · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $2 | $0 | $0 | $3 |
| % Growth | – | -100% | -91.1% | – |
| Cost of Goods Sold | $0 | $0 | $6 | $0 |
| Gross Profit | $2 | $0 | -$5 | $3 |
| % Margin | 100% | – | -1,778.5% | 100% |
| R&D Expenses | $0 | $2 | $6 | $38 |
| G&A Expenses | $5 | $8 | $13 | $21 |
| SG&A Expenses | $5 | $8 | $13 | $21 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $3 | -$6 | $0 |
| Operating Expenses | $6 | $13 | $13 | $59 |
| Operating Income | -$4 | -$13 | -$19 | -$55 |
| % Margin | -181.4% | – | -6,242.4% | -1,662.5% |
| Other Income/Exp. Net | $1 | $0 | $0 | $4 |
| Pre-Tax Income | -$3 | -$13 | -$18 | -$52 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$3 | -$5 | -$44 | -$52 |
| % Margin | -152.9% | – | -14,841.1% | -1,555.6% |
| EPS | -1.21 | -8.99 | -20.15 | -26.4 |
| % Growth | 86.5% | 55.4% | 23.7% | – |
| EPS Diluted | -1.21 | -8.99 | -20.15 | -26.4 |
| Weighted Avg Shares Out | 3 | 2 | 2 | 2 |
| Weighted Avg Shares Out Dil | 3 | 2 | 2 | 2 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$4 | -$10 | -$18 | -$54 |
| % Margin | -181.4% | – | -6,220.5% | -1,621.7% |